A new TB vaccine for adolescents and adults, developed by IIT and ILS Bhubaneswar, is set for commercialisation.

Wealthier consumptive patients had long been directed to salubrious locations such as seaside resorts or spa towns to escape ...

In a significant breakthrough, the Institute of Life Sciences (ILS), Bhubaneswar has developed a next-generation subunit ...

The vaccine triggers strong immune responses against Mycobacterium tuberculosis and is licensed for commercial development to ...

Pulmonary diseases pose a major health problem worldwide with millions of affected individuals and dire economic impact.

Tuberculosis (TB) continues to be one of the world's leading causes of infectious disease-related illness and death. Despite ...

Bhubaneswar: The Bhubaneswar-based Indian Institute of Technology (IIT), the Institute of Life Sciences (ILS) along with the ...

German researchers studying tuberculosis that spreads beyond the lungs identified unique immune patterns in patients’ blood.

Tuberculosis (TB) remains one of the world’s deadliest infectious diseases, claiming 1.23 million lives in 2024 alone, as reported by the WHO. Ending the TB epidemic by 2030 is a key global health ...

Three Indian research institutes have signed an agreement with TechInvention Lifecare Limited for the technology transfer and future commercialisation of a novel TB vaccine candidate<br />The Indian ...

Bhubaneswar: The Bhubaneswar-based Indian Institute of Technology (IIT), the Institute of Life Sciences (ILS), along with the ...

The HSP Subunit Vaccine candidate, jointly developed by the Institute of Life Sciences (ILS), Bhubaneswar, and the Indian Institute of Technology (IIT) Bhubaneswar, marks a significant advancement in ...